{"id":514,"date":"1998-05-01T12:00:00","date_gmt":"1998-05-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/neue-richtlinien-zur-diagnostik-und-behandlung-der-arteriellen-hypertonie"},"modified":"2022-03-17T14:08:46","modified_gmt":"2022-03-17T13:08:46","slug":"neue-richtlinien-zur-diagnostik-und-behandlung-der-arteriellen-hypertonie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/neue-richtlinien-zur-diagnostik-und-behandlung-der-arteriellen-hypertonie","title":{"rendered":"Neue Richtlinien zur Diagnostik und Behandlung der arteriellen Hypertonie"},"content":{"rendered":"<p>DER ARZNEIMITTELBRIEF hat mehrfach \u00fcber neuere Studien zur medikament\u00f6sen und di\u00e4tetischen Therapie der arteriellen Hypertonie berichtet (1-5). Eine umfangreiche und lesenswerte Zusammenstellung zur Diagnostik und Therapie des Bluthochdrucks sind die k\u00fcrzlich ver\u00f6ffentlichten neuen Richtlinien des VI. Reports des US Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (6). In ihrem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DER ARZNEIMITTELBRIEF hat mehrfach \u00fcber neuere Studien zur medikament\u00f6sen und di\u00e4tetischen Therapie der arteriellen Hypertonie berichtet (1-5). Eine umfangreiche und lesenswerte Zusammenstellung zur Diagnostik und Therapie des Bluthochdrucks sind die k\u00fcrzlich ver\u00f6ffentlichten neuen Richtlinien des VI. Reports des US Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (6). In ihrem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,1057,1058,438,129,128,131,324,1059,48,492,440,325,134,1060,348],"class_list":["post-514","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-alpha-2-agonisten","tag-alpharezeptoren-blocker","tag-antihypertensiva","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-blutdruck","tag-dash-studie","tag-diabetes-mellitus","tag-diuretika","tag-hane-studie","tag-hypertonie","tag-kalziumantagonisten","tag-niereninsuffizienz","tag-shep-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=514"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/514\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}